MRPL35 and gastric cancer: Later investigation by the same authors found that treatment of gastric cancer cell lines (BGC-823, MGC80-3) with 18β-glycyrrhetinic acid, a promising anti-inflammatory and antioxidant agent, inhibited MRPL35 expression and induced cancer cell apoptosis and cell cycle arrest [64].